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Neutralizing antibody responses against heterologous isolates in human immunodeficiency virus type 1
(HIV-1) and HIV-2 infections were compared, and their relationships with established clinical markers of
progression were examined. Neutralizing responses against 7 heterologous primary isolates and 1 laboratory
strain were compared between 32 untreated HIV-1-infected subjects and 35 untreated HIV-2-infected subjects
using a pseudotyped reporter virus assay. The breadth of the neutralizing response, defined as the proportion
of panel viruses positively neutralized by patient plasma, was significantly greater among HIV-2-infected
subjects than among HIV-1-infected subjects. Notably, for fully one-third of HIV-2 subjects, all viruses were
effectively neutralized in our panel. Magnitudes of responses, defined as reciprocal 50% inhibitory concentra-
tion (IC50) titers for positive reactions, were significantly greater among HIV-1-infected subjects than among
HIV-2-infected subjects. When plasma samples from HIV-1 patients were tested for cross-neutralization of
HIV-2 and vice versa, we found that these intertype responses are very rare and their prevalences comparable
in both HIV-1 and HIV-2 infection. The significantly higher magnitude of heterologous responses for HIV-1
compared to HIV-2 prompted us to examine associations with viremia, which is known to be significantly
higher in HIV-1 infection. Importantly, there was a significant positive correlation between the IC50 titer and
viral load within both the HIV-1 and HIV-2 groups, suggesting heterologous antibodies may be driven by viral
replication. We conclude that HIV-2 infection is characterized by a broad, low-magnitude intratype neutral-
ization response, while HIV-1 is characterized by a narrower but higher-magnitude intratype response and that
a significant positive association between the IC50 titer and viremia is common to both HIV-1 and HIV-2
infections.
Human immunodeficiency virus type 2 (HIV-2), like HIV-1,
causes AIDS in humans. Although they are highly related
lentiviruses, HIV-1 and HIV-2 maintain some distinct epide-
miological and biological characteristics. For example, HIV-2
is largely confined to West Africa, while HIV-1 infection is
prevalent worldwide. Importantly, disease progression occurs
much more slowly with HIV-2 (29, 30, 53), with more than 95%
of infected individuals followed for at least 8 years fitting a
clinical definition of long-term nonprogression (29). This dif-
ference makes HIV-2 a potentially important model of atten-
uated HIV infection that might provide unique insight into the
pathogenesis of HIV-1. To date, the precise mechanisms re-
sponsible for this attenuated phenotype of HIV-2 remain un-
clear. Previous studies have shown that proviral loads are com-
parable between HIV-1- and HIV-2-infected individuals (8, 36,
39). Plasma viral loads, by contrast, are significantly higher in
people infected with HIV-1 (2, 4, 39, 40, 47). This suggests that
a key difference between the two HIV types may lie in the
degree of viral replication (39), and it is presumed that host
immunity largely contributes to the more successful control of
HIV-2 infection.
Neutralizing antibody responses are critical mediators of
host defense against many human pathogens, although their
role in HIV infection remains unclear. One of the difficulties in
assessing the importance of neutralizing antibody responses in
HIV infection has been the lack of standardized neutralization
assays. This problem has been addressed by the increasing use
of HIV reporter viruses bearing primary HIV env clones, ini-
tially applied to neutralizing antibody studies by Richman et al.
(42) and Wei et al. (51). These reporter virus-based neutral-
ization assays are based on single-round infections by envelope
pseudotyped viruses, and the readout is more directly related
to the number of infection events than is the case with tradi-
tional p24 antigen-based assays, which are sensitive to viral and
target cell factors that are influenced by virus replication and
dependent on multiple rounds of virus infection.
Most of what is known about the role of neutralizing anti-
body responses in HIV infection is the result of studies of
HIV-1-infected populations or studies using nonhuman pri-
mate models. Passive-transfer experiments with simian-human
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immunodeficiency virus-infected macaques demonstrated that
preexisting neutralizing antibodies can prevent AIDS virus in-
fection (22). Additionally, some studies suggest that potent
heterologous neutralizing antibody responses contribute to the
control of HIV-1 in patients classified as long-term nonpro-
gressors (12, 13, 33, 38), although other studies have failed to
replicate these findings (7, 10, 21, 26). Most individuals re-
cently infected with HIV-1 mount a vigorous neutralizing an-
tibody response directed against autologous virus; however,
antibody escape often emerges during early infection (3, 5, 18,
34, 42, 51). By contrast, neutralizing antibody responses to
heterologous primary isolates or to laboratory strains have
been shown to be negligible or nonexistent during the first year
or two of HIV-1 infection (1, 32, 34, 42). The breadth and
magnitude of these heterologous responses may be largely
driven by HIV diversification (20, 43) and viral replication (6,
16). Given the purported differences in in vivo viral replication
between HIV-1 and HIV-2 (39), it is tempting to speculate that
qualitative differences in heterologous neutralizing antibody
responses might also exist. This is of interest, since a major
focus of the HIV vaccine effort is the development of broadly
reactive neutralizing antibodies able to retain potent and broad
activities against heterologous primary isolates (19).
To date, there have been few comprehensive studies of the
neutralizing antibody response in natural HIV-2 infection.
Some early studies suggested that autologous neutralizing an-
tibody responses to contemporaneous isolates may be more
common in people with HIV-2 infection than in those infected
with HIV-1 (9, 17, 19, 48). Few studies have comprehensively
examined the neutralizing antibody response against heterol-
ogous primary isolates in HIV-2-infected individuals. One re-
cent study demonstrated potent neutralization against heter-
ologous primary HIV-2 isolates among a small number of
HIV-2-infected subjects (46); however, this study was limited
to patients who were antiretroviral therapy-experienced and/or
had clinically progressed and utilized a nonstandard neutral-
ization assay.
Potent heterologous neutralizing antibody responses in
HIV-2 infection might suggest that antibodies are more easily
able to neutralize HIV-2 or that people infected with HIV-2
possess a uniquely flexible host antibody repertoire. Either
interpretation would support the hypothesis that neutralizing
antibody responses are especially robust in HIV-2 infection,
correlating with its suppressed replication and pathogenesis. In
order to directly compare plasma neutralizing activity against
heterologous primary isolates between HIV-1- and HIV-2-
infected subjects, plasma samples from 32 antiretroviral ther-
apy-naive HIV-1-infected subjects were compared to those
from 35 antiretroviral therapy-naive HIV-2-infected subjects
using a pseudotyped reporter virus assay.
MATERIALS AND METHODS
Study population. This study was conducted with women enrolled in an on-
going prospective clinical cohort of registered female sex workers in Dakar,
Senegal, which has been followed since 1985. Various epidemiological and clin-
ical aspects of this cohort have been reported previously (25). All subjects signed
informed consent and participated in protocols approved by the Counseil Na-
tional de Lutte Contre le Sida Comite Ethique et Juridique and the Harvard
School of Public Health Human Subjects Committee, in accordance with the
Federal Office of Human Research Protections regulations. HIV serostatus and
CD4 T-cell counts were determined as described previously (25). All subjects
were free of dual HIV-1/HIV-2 infection. Plasma samples for viral RNA were
collected beginning in 1996; blood was collected in EDTA-containing tubes and
the plasma stored at 70°C within 6 h of collection, following separation by use
of Ficoll-Hypaque (Organon Teknika Cappel; Durham, NC). Viral loads were
determined as described below. All subjects had been infected with HIV for 6
years. The time of infection for seroincident women was estimated to be the
midpoint between the dates of their last seronegative and first seropositive
bleeds. All subjects enrolled in this study were antiretroviral therapy naive and
had CD4 T-cell counts of 200/l at the time of sample acquisition.
Quantification of plasma viral loads. HIV-1 plasma viral loads were deter-
mined using a commercially available assay (Amplicor HIV-1 monitor test,
version 1.5; Roche, Basel, Switzerland). To determine HIV-2 viral loads, an
in-house real-time PCR viral load assay was developed. Full-length HIV-2
genomic RNA from a previously described in vitro infection (28) was extracted
(QIAamp viral RNA mini-kit; QIAGEN, Valencia, CA), treated with DNase
(New England Biolabs; Ipswich, MA), and repurified (MEGAclear; Ambion,
Foster City, CA). Quantification of this genomic HIV-2 RNA was determined
using in vitro-transcribed HIV-2 RNA generated as follows. Briefly, to construct
a quantitative standard, a fragment of the HIV-2 long terminal repeat-gag gene
was amplified (from a previously cloned HIV-2 DNA sample) using primers
HIV2gagF (CCA ACC ACG ACG GAG TGC TC) and AM2gag1r (CAA TTC
ATT CGC TGC CCA CAC) and cloned into an in vitro transcription construct
using commercially available reagents (BLOCK-iT RNAi TOPO transcription
kit; Invitrogen, Carlsbad, CA). RNA was generated by in vitro transcription
(MEGAshortscript; Ambion, Foster City, CA), purified (MEGAclear; Ambion,
Foster City, CA), treated with DNase (New England Biolabs, Ipswich, MA), and
repurified. The concentration of in vitro-transcribed RNA was determined from
an optical density reading at 260 nm and used to generate a quantitative standard
of full-length HIV-2 genomic RNA in a two-step real-time reverse transcription-
PCR (RT-PCR) assay (Taqman reverse transcription reagents and Taqman
universal PCR master mix; Applied Biosystems, Foster City, CA) using primers
HIV2gagF and HIV2gagR (CTC TCA AGA CGG AGT TTC TCG C), and
RNA was detected using the probe HIV2gagP (AGG CCT CCG GGT GAA
GGT AAG), which contained a 5 6-carboxyfluorescein fluorescent reporter and
a 3 MGB nonfluorescent quencher. For quantification of plasma viral loads,
RNA standard curves were generated from the full-length HIV-2 genomic RNA.
This standard-curve RNA was added to noninfected lysis buffer and extracted in
parallel with HIV-2 plasma samples (QIAamp viral RNA mini-kit; QIAGEN,
Valencia, CA). Viral RNA was quantified relative to the HIV-2 genomic RNA
standard curve in the two-step real-time RT-PCR assay described above.
env amplification. HIV genomic RNA or DNA was isolated from either
plasma or peripheral blood mononuclear cells (QIAamp viral RNA mini-kit and
blood and cell culture DNA mini-kit; QIAGEN, Valencia, CA). env was ampli-
fied in a nested RT-PCR from plasma RNA using a one-step RT-PCR assay kit
(SuperScript One-Step RT-PCR kit; Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions and using first-round primers H1R1F (TAG GCA
TCT CCT ATG GCA GGA AGA A) and H1R1R (TAA ATC TTG AGA TRC
TGC TCC TAC TC) for HIV-1 and H2R1F (CTY ATT TTC CAG GTS TGG
TST GGC ARA GGT) and H2R1R (TCT CCA TGG GGT GTT TTC AT) for
HIV-2. Second-round PCRs were performed using primers H1R2F (CAC CGA
ATA AGA GAA AGA GCA GAA GAY A) and H1R2R (CTT TTT GAC CAC
TTG CCM CCC AT) for HIV-1 and H2R2F (CTA GGT ACC GTA TGA TGT
GTG GTA AGA GT) and H2R2R (TGC GGA TCC TCA CAG GAG GGC
GAT TTC TGC) for HIV-2. Where proviral DNA was used as a template, the
same primer pairs described above were used in a nested PCR. Blunt-ended PCR
products, representing env pools, were cloned into the pcDNA 3.1 directional
cloning vector according to the manufacturer’s instructions (Invitrogen, Carls-
bad, CA). env expression vectors were expanded in 300-ml cultures, purified
(QIAGEN MaxiPrep kit; QIAGEN, Valencia, CA), and quantified and purity
assessed by using a spectrophotometer.
Neutralizing antibody assay. Reporter virus particles containing subject Env
proteins were produced by cotransfecting 293T cells with env expression vectors
(10 g) plus an env-deficient HIV-1 genomic vector, pNL4-3.Luc.R-E- (20 g),
that contains a firefly luciferase indicator gene (obtained through the NIH AIDS
Research and Reference Reagent Program).
A panel of eight HIV-1 reporter viruses was used. Seven of these carried
primary patient-derived Env proteins from epidemiologically unlinked HIV-1
CRF02_AG-infected individuals (CRF02_AG is the most prevalent HIV-1 strain
in our cohort (31, 44), and one carried the Env protein from the neutralization-
sensitive laboratory strain NL4-3. A panel of eight HIV-2 reporter viruses was
used. Seven of these carried primary patient-derived Env proteins from epide-
miologically unlinked HIV-2-infected individuals, and one carried the Env pro-
tein of laboratory-strain CBL23 (initially described in reference 45).
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Recombinant viruses pseudotyped with patient-derived virus Env proteins
were harvested 48 h posttransfection, centrifuged, and quantified for p24 content
using a commercial enzyme-linked immunosorbent assay (Alliance HIV-1 p24
Antigen ELISA kit; Perkin-Elmer, Wellesley, MA). All viruses were screened to
ensure they were functional for infection and yielded high luciferase readings in
lysates of target cells prior to use in neutralization assays. The neutralizing
antibody assay used was based on the pseudotyped reporter virus system as
described by Richman et al. (42). Briefly, 750 pg of HIV pseudoviruses (based on
p24 content) were incubated for 1 h at 37°C with fivefold dilutions of heat-
inactivated patient plasma samples. Repeated controls using a range of virus
input values were run to verify that luciferase expression correlated directly with
the amount of virus inoculum used but that the neutralization titer was largely
independent of the virus inoculum. All dilutions were normalized to contain 10%
total human plasma using normal donor plasma. U87 cells expressing CD4 and
the CCR5 and CXCR4 coreceptors were then inoculated with virus-plasma
dilutions in the absence of added cations. Virus infectivity was determined 72 h
postinoculation by measuring the amount of luciferase activity expressed in
infected cells. Background luminescence was measured using control wells that
contained only target cells and medium. Luciferase activity was quantified using
a commercial luciferase assay kit (Steady-Glo luciferase assay system; Promega),
and plates were read on a microplate luminometer.
Neutralizing activity was displayed as the percent inhibition of viral infection
(luciferase activity) at each antibody dilution compared to an antibody-negative
control: percent inhibition  [1  (luciferase with antibody/luciferase without
antibody)]  100. Fifty percent inhibitory concentration (IC50) titers were cal-
culated using the BioDataFit HTP 1.2 program as the reciprocal of the plasma
dilution conferring 50% inhibition relative to negative plasma controls. To mon-
itor the amount of neutralization activity that is not HIV Env protein specific,
each plasma sample was also tested against a pseudovirus carrying the vesicular
stomatitis virus (VSV) envelope protein (obtained through the NIH AIDS Re-
search and Reference Reagent Program). These VSV envelope proteins are able
to mediate virus entry into the target cells used but are not inhibited by anti-HIV
Env antibodies. Sera from 10 HIV-negative individuals from the same cohort
were also used as controls against all pseudoviruses tested. The reproducibility of
the assay was examined by repeatedly testing the laboratory strain viruses HIV-1
NL4.3 and HIV-2 CBL23 using the same HIV-1 (for NL4.3) and HIV-2 (for
CBL23) pooled plasma samples composed of samples from five randomly se-
lected subjects. Using this control, the reproducibility of the assay within and
between runs was found to be within 2.8-fold.
Statistical analysis. Statistical analysis was performed using the STATA sta-
tistical software package (STATA, version 9.0; StataCorp, College Station, TX).
IC50 titers were calculated using the BioDataFit HTP 1.2 program (Chang
Bioscience, Castro Valley, CA). Unadjusted comparisons in breadth and mag-
nitude of neutralizing antibody responses between groups were performed using
the Mann-Whitney test. To adjust for CD4 T-cell counts and age when com-
paring HIV-1-infected subjects to HIV-2-infected subjects, multivariate regres-
sion analyses were performed. All correlations were examined using either the
Pearson’s or the Spearman’s correlation coefficient.
RESULTS
Subject characteristics. We examined heterologous neutral-
izing antibody responses for 32 HIV-1-infected individuals and
35 HIV-2-infected individuals (Table 1). The HIV-1-infected
subjects (median age [interquartile range {IQR}]  36 [31 to
42]) were younger than the HIV-2-infected subjects (median
age [IQR]  40 [36 to 42.5]; P  0.005). Although all subjects
were in the asymptomatic phase of HIV infection, CD4 T-cell
counts were lower for HIV-1-infected subjects (median cells/l
[IQR]  575 [448 to 805]) than for HIV-2-infected subjects
(median cells/l [IQR]  760 [531 to 969]; P  0.0315). Con-
sistent with previous reports (2, 4, 39, 40, 47), plasma viral
loads were significantly higher for HIV-1-infected subjects
(median log10 copies/ml [IQR]  4.01 [3.62 to 4.57]) than for
HIV-2-infected subjects (median log10 copies/ml [IQR]  2.6
[2.6 to 3.1]; P  0.009).
Pseudotyped-virus characteristics. Patient-derived HIV-1
and HIV-2 env genes were used to produce reporter-
pseudotyped virus with an env-deficient HIV-1 genomic vector
(pNL4-3.Luc.R-E-) engineered to express a luciferase reporter
gene (14). The use of the pNL4.3.Luc-R-E backbone with
HIV-2 Env proteins to produce infection-competent pseudovi-
ruses has been reported previously (23, 24). To ensure that all
pseudotyped viruses were functional and capable of mediating
infection into target cells, purified virus preparations were an-
alyzed in a single-round infectivity assay (37, 42). Figure 1
demonstrates that all HIV-1- and HIV-2-pseudotyped viruses
used in the study showed infectivity for U87/CD4/CCR5/
CXCR4 cells, albeit to various levels. Overall, HIV-1 and
HIV-2 pseudoviruses demonstrated comparable infectivity ef-
ficiencies in our assay system.
Although there was variability within subjects (to different
pseudoviruses) and between subjects, the neutralization assay
consistently generated neutralization curves similar in shape
and slope for the HIV-1 and HIV-2 groups (data not shown).
IC50s are reported as they are taken at the inflection of a
sigmoid curve and can therefore be estimated with greater
confidence than 90% inhibitory concentrations. Importantly,
comparable IC50s resulted in comparable nonneutralized frac-
tions between the HIV-1 and HIV-2 groups (i.e., inhibition
curves typically plateaued at comparable percent neutraliza-
tion).
Breadth of heterologous neutralizing antibody responses.
We first examined the breadth of neutralizing antibody re-
sponses against our panel of heterologous reporter viruses. A
response was considered positive for neutralization if the IC50
titer against the HIV reporter virus was 3-fold higher than
that against the VSV control.
The breadths of the responses were generally lower for HIV-
1-infected subjects than for HIV-2-infected subjects (P value
0.041) after adjusting for age and CD4 T-cell counts (Fig. 2).
Plasma from HIV-1-infected subjects neutralized a median of
57% (IQR, 43% to 57%) of viruses in the panel, while plasma
from HIV-2-infected subjects neutralized a median of 86%
(IQR, 57% to 100%) of the viruses in their panel. Among our
HIV-2-infected subjects, all 35 subjects (100%) neutralized at
least 1 virus in the panel and, surprisingly, almost one-third
(31%) neutralized all 7 primary heterologous viruses in the
panel.
TABLE 1. Study population characteristics by groupa
Patient cohort (nb) Age (yr) CD4
 T-cell count
(cells/mm3)




HIV-1 infected (32) 36 (31–42) 575 (448–805) 4.01 (3.62–4.57) 8.6 (7.8–10.5)
HIV-2 infected (35) 40 (36–42.5) 760 (531–969) 2.6 (2.6–3.1) 9.1 (6–10.5)
a Values are medians, with IQRs given in parentheses.
b n, no. of patients.
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There was no significant association between breadth of
response (in terms of proportion of viruses neutralized) and
CD4 T-cell count for either the HIV-1-infected (r 0.11; P
0.532) or HIV-2-infected (r  0.06; P  0.845) infected group.
However, within the HIV-1-infected group, there was a posi-
tive association between breadth of response and viremia (r 
0.41; P  0.039).
Together these results suggest that compared to the case
with HIV-1 infection, the heterologous neutralizing antibody
response in asymptomatic HIV-2 infection is broad, with most
serum samples able to neutralize a majority of the viruses in
the panel.
Magnitude of heterologous neutralizing antibody responses.
The magnitude of the responses was defined based on the
median IC50 titer against all primary heterologous viruses.
Although responses varied widely between subjects, the mag-
nitudes of the responses were significantly greater (P  0.035)
among HIV-1-infected subjects (median IC50 titer [IQR] 
285 [186 to 340]) than among HIV-2-infected subjects (median
IC50 titer [IQR] 117 [100 to 167]) after adjusting for age and
CD4 T-cell counts (Fig. 3A). Within the HIV-1 group, IC50
titers against the laboratory strain NL4.3 were significantly
higher (p  0.008) than responses against the reporter viruses
carrying patient-derived Env proteins. Within the HIV-2
group, IC50 titers against the CBL23 isolate were only slightly
higher (P  0.082) than responses against the patient-derived
reporter viruses.
As shown in Fig. 3B, there was a significant positive associ-
ation between the magnitude of responses (in terms of average
IC50 titer against all viruses) and plasma viral load both within
the HIV-1-infected group (r  0.63; P  0.011) and within the
HIV-2-infected group (r  0.59; P  0.017). No association
was found between the magnitude of the neutralizing re-
sponses and CD4 T-cell counts in either the HIV-1-infected
(r  0.38; P  0.182) or HIV-2-infected (r  0.22; P  0.374)
population.
These results suggest that although HIV-2-infected individ-
uals have broad heterologous neutralizing antibody responses,
these responses are generally of low titer compared to those in
HIV-1 infection. Further, the significant positive associations
we found between the magnitude of neutralizing responses and
viremia in both HIV-1- and HIV-2-infected groups suggest
that heterologous neutralizing antibody responses may be
driven by viral replication in HIV infection.
Cross-neutralization responses. The significant breadth of
the heterologous neutralizing antibody response we observed
in our HIV-2-infected subjects prompted us to investigate
whether plasmas from these individuals are able to neutralize
primary HIV-1 reporter viruses and vice versa. Cross-neutral-
izing antibodies were assessed in a subgroup of 24 HIV-1-
infected subjects and 24 HIV-2-positive subjects, randomly
FIG. 1. Infectivities of pseudoviruses carrying HIV-1 or HIV-2 Env proteins. Virus stocks were generated by cotransfecting 293T cells with
vectors carrying HIV-1 and HIV-2 env genes with pNL4.3.Luc-R-E. Infectivity was determined by infection of U87/CD4/CCR5/CXCR4-expressing
target cells and measurement of luciferase light signals in target cell lysates per nanogram of p24. Error bars represent standard errors from three
independent experiments. Infectivity values for pNL4.3- and CBL23-bearing cells as well as the backbone pNL4.3.Luc-R-E are shown for controls.
FIG. 2. Breadth of neutralizing antibody responses against a panel
of heterologous HIV pseudoviruses among patients with asymptomatic
chronic-stage HIV-1 (n  32) or HIV-2 (n  35) infection. Breadth
was defined as the percentage of viruses in the panel neutralized by
subject plasma, where a positive response is defined as an IC50 titer
against the HIV pseudovirus that is 3-fold the response against a
VSV pseudovirus. Plasma from HIV-2-infected subjects neutralized a
significantly greater proportion of heterologous viruses than did
plasma from HIV-1-infected subjects (P  0.041).
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selected from the larger study groups in the cross-sectional
analysis, using the same panel of HIV-1 and HIV-2 reporter
viruses described above.
As shown in Fig. 4, among the 24 samples from HIV-1-
infected subjects, only 4 (25%) scored positive for neutraliza-
tion against any of the HIV-2 viruses in the panel. In total, of
the 168 HIV-1 plasma/HIV-2 virus combinations, only 7 (4%)
were positive for cross-neutralization. Among the 24 samples
from HIV-2-infected subjects, only 9 (38%) were positive for
neutralization against any of the HIV-1 viruses in the panel. In
total, of the 168 HIV-2 plasma/HIV-1 virus combinations, only
15 (9%) were positive for neutralization. There was not a
significant difference in the prevalence of intertype cross-neu-
tralizing responses between HIV-1- and HIV-2-infected sub-
jects (P  0.195). Notably, the HIV-1 laboratory strain NL4-3
was significantly more sensitive to cross-neutralization than
were the patient-derived viruses (P  0.008). Sixty-five percent
of the HIV-2 subject samples tested were positive for neutral-
ization against this virus, with an average IC50 titer of 325. This
result is consistent with the high sensitivity of this virus to
neutralization and suggests that HIV-1 and HIV-2 share com-
mon neutralization epitopes that may be uniquely exposed on
the NL4.3 envelope.
DISCUSSION
Comparing neutralizing antibody responses between HIV-1-
and HIV-2-infected individuals using standardized assays is
FIG. 3. Magnitude of neutralizing antibody responses against a panel of heterologous HIV pseudoviruses among patients with asymptomatic
HIV-1 (n  32) or HIV-2 (n  35) infection. (A) Comparison of the magnitude of neutralizing antibody responses against HIV reporter viruses.
The magnitude of the responses was defined based on the median IC50 titer against all primary heterologous viruses, where a response was positive
for neutralization. For HIV-1-infected subjects, the magnitude of neutralizing response against heterologous viruses was significantly higher than
that for HIV-2-infected subjects (P  0.035). (B) Relationship between magnitude of neutralizing antibody response and viral load for HIV-1-
infected (triangles) or HIV-2-infected (circles) subjects. There was a significant positive correlation between viremia and the magnitude of the
neutralizing response for HIV-1-infected (r  0.63; P  0.011) and HIV-2-infected (r  0.59; P  0.017) groups.
FIG. 4. Intertype cross-neutralization of HIV-2 pseudoviruses by
plasma from HIV-1-infected subjects (n  24) and neutralization of
HIV-1 pseudoviruses by plasma from HIV-2-infected subjects (n 
24). There was no significant difference in the proportions of HIV-1-
and HIV-2-infected subjects, demonstrating positive neutralization
against intertype viruses (P  0.195).
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important to our understanding of the mechanisms responsible
for the attenuated pathogenesis of HIV-2 relative to that of
HIV-1 and may shed light on the role of these responses in
HIV-1 infection. This is the first study, to our knowledge, to
apply the HIV reporter virus system to directly compare the
heterologous neutralizing antibody responses for HIV-1- and
HIV-2-infected individuals. Our findings demonstrate several
important characteristics of the heterologous neutralizing an-
tibody response in HIV-1 and HIV-2 infection and highlight
some interesting differences between the two groups.
In this study we demonstrate that individuals with chronic
HIV-2 infection maintain very broad neutralizing antibodies,
with about one-third of the subjects able to neutralize all seven
of the primary viruses in the panel. By comparison, HIV-1-
infected subjects neutralized a median of three of the viruses in
our panel. The ability of an HIV-2-infected subject to neutral-
ize viruses from other individuals suggests that important neu-
tralizing determinants must be shared between viruses isolated
from different individuals. Homogeneity at important neutral-
ization domains would, in essence, reduce the distinction be-
tween heterologous and autologous viruses and result in ex-
tensive cross-reactivity. This interpretation is also supported by
our results demonstrating that none of the HIV-2 reporter
viruses in our panel, derived from epidemiologically unlinked
subjects at different stages of infection, was atypically resistant
or sensitive to neutralization. On the other hand, two HIV-1
viruses in our panel seemed to be particularly resistant to
neutralization by heterologous plasma. Considering the selec-
tive pressure neutralizing antibodies can impose on viral pop-
ulations, our results suggest that functional constraints may
exist to limit evolution of neutralizing domains of the HIV-2
envelope and that this property may be different for the HIV-1
virus. Elucidating this property may provide important infor-
mation for the design of immunogens able to induce broadly
reactive neutralizing antibodies in HIV infection.
Beyond envelope sequence diversity, higher CD4 T-cell
counts (13) and longer durations of HIV infection (34) have
also been associated with the breadth of the heterologous
neutralizing antibody response. Although our HIV-2-infected
individuals did have higher median CD4 T-cell counts than
our HIV-1-infected subjects, we did not find any association
between this measure and either the breadth or the magnitude
of the neutralizing antibody response. Additionally, all of our
comparisons between HIV-1-infected subjects and HIV-2-in-
fected subjects were performed using multivariate regression
models in which we adjusted for CD4 T-cell counts. Further,
although our HIV-2-infected subjects were older, there was no
significant difference in the duration of HIV infection between
our HIV-1-infected subjects and our HIV-2-infected subjects.
Therefore, we feel that these issues have not significantly af-
fected our interpretation of the data from this study.
It remains unclear from our results whether these broad
responses represent a uniquely diverse antibody repertoire or
that the HIV-2 envelope is especially prone to neutralization.
It is possible that, similar to what was shown with T-cell-
receptor flexibility and broad cytotoxic-T-lymphocyte re-
sponses in HIV-2 infection (27), broad antibody responses
represent B-cell receptor heterogeneity. Reeves and Doms
have hypothesized (41) that HIV-2 may be prone to neutral-
ization due to a more “open” coreceptor binding site confor-
mation or that the functionally important positions (neutraliz-
ing domains) in the HIV-2 envelope are more genetically
constrained. However, the results from the work of Decker et
al. (15) demonstrate that HIV-1 patients maintain robust
cross-neutralizing antibodies that are almost exclusively depen-
dent on CD4 binding, suggesting that the HIV-2 coreceptor
binding site is not accessible to neutralizing antibodies in its
normal conformation.
In 1995, we first reported a retrospective epidemiologic anal-
ysis of the Dakar cohort that suggested that HIV-2 infection
provided approximately 70% protection from subsequent
HIV-1 infection (49, 50). It has been hypothesized that a po-
tent cross-reactive immune response might contribute to this
protection (41), with neutralizing antibodies being an obvious
prime candidate. Our results in this report, however, suggest
that such cross-neutralizing antibodies are extremely rare in
HIV-2- or HIV-1-infected individuals. This is contrary to re-
ports from some early studies that plasma from HIV-2-infected
individuals was able to neutralize HIV-1 isolates (17, 52). This
discrepancy is likely the result of methodological differences,
since early studies used laboratory-adapted HIV isolates that
are generally uniquely sensitive to plasma neutralization (11,
35) and used replication-competent viruses capable of multiple
rounds of replication. It is possible, however, that HIV-2 pa-
tients do maintain CD4-induced antibodies able to neutralize
HIV-1, since this relationship was shown to exist in the oppo-
site direction by Decker et al. (15).
Although broad, our study demonstrates that heterologous
neutralizing antibody responses in HIV-2 infection are gener-
ally of very low magnitude compared to those in HIV-1 infec-
tion. The low-titer response in HIV-2 infection may likely
result from the suppressed viral replication and antigenic stim-
ulation in HIV-2 infection in vivo compared to those of HIV-1
infection (MacNeil et al., submitted for publication). Lending
strong support to this interpretation, we demonstrate here a
significant positive correlation between IC50 titers and plasma
viral load in both the HIV-1 and HIV-2 groups. A similar
relationship was recently demonstrated in a study of HIV-
1-infected individuals (16), suggesting that the association
between viremia and the magnitude of the heterologous neu-
tralizing response is a common characteristic of HIV infection.
It is difficult to interpret the clinical importance of heterol-
ogous neutralizing antibody responses to the control of HIV-1
or HIV-2 infection based on our findings. Against the argu-
ment that heterologous responses are clinically important in
HIV infection, we demonstrate a strong positive association
between IC50 titers and viral load levels in both HIV-1- and
HIV-2-infected groups. This suggests that the magnitude of the
heterologous response is driven by viral replication, which
would be expected to inversely correlate with clinical status.
However, since all of our subjects fell within the asymptomatic
phase of HIV infection, any conclusions extending to symp-
tomatic patients should be made with caution.
Our study has several shortcomings that must be mentioned.
First, our study lacks an analysis of neutralizing antibody re-
sponses against autologous viruses. This information is critical
to understanding the role of neutralizing antibodies and viral
evolution in HIV infection and how they may differ between
HIV-1 and HIV-2 infection. Such an analysis is technically
difficult in HIV-2 due undetectable viral loads in a majority of
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HIV-2-infected individuals, making the cloning of env se-
quences from the plasma compartment very difficult for a ma-
jority of asymptomatic individuals. Bailey et al. (6) demon-
strated that env cloning can be accomplished with patients with
undetectable viral loads, but this technique utilized large vol-
umes of patient plasma that are unattainable in our cohort
design. Second, we utilized a cross-sectional analysis in this
study, which makes it difficult to elucidate cause and effect
relationships between neutralization responses and clinical
markers. Third, the low numbers of subjects who progress
clinically from HIV-2 infection limits our ability to dissect and
compare the differences in neutralizing antibody responses
between HIV-1- and HIV-2-infected individuals able to con-
trol their infection and those who progress to AIDS.
In conclusion, we demonstrate that heterologous neutraliz-
ing antibody responses in HIV-2 infection are generally broad,
suggesting that circulating HIV-2 viruses in Senegal share com-
mon neutralization domains. We suggest these results may be
indicative of constraints on viral evolution that may differ for
HIV-1. Additionally, the significantly lower magnitudes of neu-
tralizing responses in HIV-2 infection seem to represent the
suppressed in vivo viral replication of this virus compared to
the case with HIV-1 infection. Similarly, the positive associa-
tion between heterologous responses and viral load further
suggest these responses are driven by viral replication. Finally,
we demonstrate that intertype cross-neutralizing responses are
extremely rare in both HIV-1 and HIV-2 infections.
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